Who is sponsoring NCT03349892?

NCT03349892 is sponsored by University of California, Los Angeles.

What condition does NCT03349892 study?

NCT03349892 studies Refractory Ventricular Tachycardia.

What drugs are being tested in NCT03349892?

Interventions: Stereotactic Ablative Radiotherapy (SABR).

What is the status of NCT03349892?

NCT03349892 is currently COMPLETED.

Last reviewed 2021-11-15 · How we verify

Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia

NCT03349892 NA COMPLETED Results posted

Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac myocardium and to make a preliminary assessment of the efficacy of the treatment. The dose escalation will be guided by Time-to-Event Continual Reassessment Method (TITE-CRM) to ensure more patients will be spared dose limiting toxicities and more patients will be entered on the dose level that will be chosen as minimal dose of maximal effect. This design also allows for continual accrual of patients when delayed adverse events may be observed.

Details

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	COMPLETED
Enrolment	1
Start date	Sat Apr 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Refractory Ventricular Tachycardia

Interventions

Stereotactic Ablative Radiotherapy (SABR)

Countries

United States